Since increased levels of IL-6 in the tumor site or plasma are associated with a worse prognosis for patients with advanced hepatocellular carcinoma (HCC), inhibiting the IL-6 pathway may enhance current HCC therapeutic approaches [20] (Figure 2). This evidence concerns the gene IL6 and neoplasm.